Raymond James Trust N.A. Has $30.96 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Raymond James Trust N.A. grew its position in Eli Lilly and Company (NYSE:LLY) by 0.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 34,943 shares of the company’s stock after buying an additional 240 shares during the period. Raymond James Trust N.A.’s holdings in Eli Lilly and Company were worth $30,957,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Westwood Holdings Group Inc. increased its position in Eli Lilly and Company by 5.4% during the 1st quarter. Westwood Holdings Group Inc. now owns 3,839 shares of the company’s stock worth $2,987,000 after buying an additional 196 shares during the period. Guardian Capital LP lifted its holdings in shares of Eli Lilly and Company by 3.0% during the 1st quarter. Guardian Capital LP now owns 921 shares of the company’s stock worth $717,000 after acquiring an additional 27 shares during the period. Linscomb Wealth Inc. increased its stake in Eli Lilly and Company by 0.5% in the first quarter. Linscomb Wealth Inc. now owns 3,389 shares of the company’s stock valued at $2,637,000 after acquiring an additional 17 shares during the last quarter. Steel Grove Capital Advisors LLC raised its position in Eli Lilly and Company by 104.9% during the first quarter. Steel Grove Capital Advisors LLC now owns 795 shares of the company’s stock valued at $618,000 after purchasing an additional 407 shares in the last quarter. Finally, Beck Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 1.9% in the 1st quarter. Beck Capital Management LLC now owns 8,824 shares of the company’s stock valued at $6,865,000 after purchasing an additional 163 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Citigroup boosted their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Guggenheim upped their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $1,007.94.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $748.91 on Friday. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The company’s 50 day moving average price is $868.53 and its two-hundred day moving average price is $869.14. The stock has a market cap of $710.96 billion, a P/E ratio of 80.96, a P/E/G ratio of 2.76 and a beta of 0.43. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. During the same quarter last year, the business posted $0.10 earnings per share. The business’s revenue was up 20.4% compared to the same quarter last year. On average, equities analysts predict that Eli Lilly and Company will post 13.21 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.69%. Eli Lilly and Company’s payout ratio is currently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.